Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Katsuaki OgushiMasanori AtsukawaHaruki UojimaHisashi HidakaKazushi NumataSatoshi KobayashiShunji HiroseNobuhiro HattoriTomoaki FujikawaTakahide NakazawaNaohisa WadaShuitirou IwasakiTaito FukushimaYusuke SanoMakoto UenoKuniyuki KawanoKota TsuruyaMasako ShomuraTsunamasa WatanabeKotaro MatsunagaYosuke KunishiYusuke SaigusaKuniyasu IrieShogo IwabuchiMakoto KakoManabu MorimotoTatehiro KagawaKatsuaki TanakaShin MaedaPublished in: Clinical and experimental gastroenterology (2020)
Lenvatinib treatment offers significant benefits in patients with good liver function in real-world practice. The various characteristics identified in this study might be helpful as clinical predictors of response to lenvatinib and survival in clinical practice. Further studies are required to address eligibility for lenvatinib treatment in CP 7 patients.